Meeting Banner
Abstract #3885

Multicenter, Intraindividual Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for MRA of the Peripheral Arteries

Tim Leiner1, Suzanne Gerretsen1, Thierry le Maire2, Stephan Miller3, Siegfried Thurnher4, Christoph U. Herborn5, Henrik Michaely6, Harald Kramer7, Angelo Vanzulli8, Josef Vymazal9, Martin Wasser10

1Department of Radiology, Maastricht University Hospital, Maastricht, Netherlands; 2Department of Radiology, Catharina Hospital, Eindhoven, Netherlands; 3Department of Diagnostic and Interventional Radiology, Eberhard-Karls University, Tbingen, Germany; 4Department of Radiology, Hospital of St. John's of God, Vienna, Austria; 5Medical Prevention Center, University Medical Center, Hamburg-Eppendorf, Germany; 6Department of Clinical Radiology, University Hospital Mannheim, Mannheim, Germany; 7Institute of Clinical Radiology, Ludwig Maximilians University, Munich, Germany; 8Radiologia, Ospedale Niguarda Ca' Granda, Milan, Italy; 9Department of Radiology,, Homolce Hospital, Prague, Czech Republic; 10Department of Radiology, Leiden University Medical Center, Leiden, Netherlands

This study intraindividually compared 0.1 mmol/kg bodyweight doses of gadobenate dimeglumine (MultiHance; Gd-BOPTA) and gadopentetate dimeglumine (Magnevist; Gd-DTPA) for contrast-enhanced MRA in 96 patients with peripheral arterial occlusive disease. Preference for Gd-BOPTA was expressed by each of three off-site blinded readers for all qualitative endpoints in each of three vascular territories. Likewise significantly (p≤0.0001) higher CNR was noted for Gd-BOPTA by each reader in each vascular territory. Overall, Gd-BOPTA at 0.1 mmol/kg demonstrated significantly better diagnostic performance compared to an equivalent dose of Gd-DTPA for CE-MRA of the peripheral vasculature.